Personalis Inc., a prominent cancer genomics company, announced on Tuesday that it has formed a partnership with ClearNote Health Inc., a firm specializing in cancer detection. The goal is to further develop the epigenomic 5-hydroxymethylcytosine or 5hmC platform.
According to Personalis, the cutting-edge technology will facilitate brisk developments in personalized cancer therapies due to its ability to track changes in 5hmC levels. This process is powered by innovative AI-based analytical methods that hold promise for detecting cancer at an earlier stage.
As it stands, shares of Personalis are currently selling on the Nasdaq at $1.49, which represents a 2.61 percent drop.
